Oak Hill Bio
PrivateLast Round
Series A
Jun 1, 2026
Total Funding Raised
$32.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Oak Hill Bio is a biotechnology company that acquires and develops deprioritized late-stage rare disease drugs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oak Hill Bio Comparables
Compare Oak Hill Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 80% | |
| CourageAS Biotherapeutics | 77% | |
| MavriX Bio | 74% |
Oak Hill Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 1, 2026 | ||||
| Seed | Feb 1, 2022 |
Oak Hill Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A |
| Balyasny Asset Management L.P. | Series A |
| venBio | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 57% MoM.
- Jun 1, 2026
$33M round led by Balyasny Asset Management, Janus Henderson, and venBio.
Recent news
Latest coverage and updates
- is_developingSep 3, 2026
Oak Hill Bio Ltd is developing Angelman therapies.
- is_developingJul 29, 2026
Oak Hill Bio Ltd was planning to develop antisense oligonucleotide drug, rugonersen on Jul 27th '26.
- is_developingJul 28, 2026
Oak Hill Bio Ltd is developing Rugonersen on Jul 1st '26.
- is_developingJul 28, 2026
Oak Hill Bio Ltd is developing antisense therapy rugonersen on Jul 28th '26.
- receives_financingJul 28, 2026
Oak Hill Bio Ltd was planning to receive financing of $32.5M in Series A on Jun 1st '26.
Oak Hill Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Oak Hill Bio's valuation, stock price, and market status.
Is Oak Hill Bio a public or private company?
Oak Hill Bio is a private company.
What is the current stock price of Oak Hill Bio?
Oak Hill Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Oak Hill Bio worth (valuation)?
Valuation information for Oak Hill Bio is not publicly available.
Can I buy Oak Hill Bio stock?
Oak Hill Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Oak Hill Bio's last funding round?
Oak Hill Bio's most recent funding round was Series A on June 1, 2026.
Who are the main investors in Oak Hill Bio?
Key investors in Oak Hill Bio include Janus Henderson Group, Balyasny Asset Management L.P., venBio.
Will Oak Hill Bio IPO soon?
No public IPO plans have been announced for Oak Hill Bio.
How can I track Oak Hill Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Oak Hill Bio's secondary market activity and sign up for updates.